Trial Profile
A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 7-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25 ug (Micrograms) in Children Aged 5-11 Years With Persistent Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Vilanterol (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors GSK
- 19 Oct 2011 New trial record